Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trialNov 5Quarterly updateCollegium Pharmaceutical, IncLatigo Biotherapeutics
Zevra Therapeutics posts results for Phase 2 SDX trial in idiopathic hypersomniaJun 30Trial updateserdexmethylphenidateZevra Therapeutics, Inc.